Hepatitis Monthly

Published by: Kowsar

LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes

Yuan Liu 1 , * , Ziying Zou 1 , Bing Zhu 1 , Zonghai Hu 1 , Ping Zeng 2 and Lijuan Wu 3
Authors Information
1 Department of Microbiology and Immunology, Laboratory Medicine Center, General Hospital of Chengdu Military Region of PLA, Chengdu, China
2 Department of Clinical Chemistry, Laboratory Medicine Center, General Hospital of Chengdu Military Region of PLA, Chengdu, China
3 Laboratory Medicine Center, General Hospital of Chengdu Military Region of PLA, Chengdu, China
Article information
  • Hepatitis Monthly: May 01, 2015, 15 (5); e28473
  • Published Online: May 23, 2015
  • Article Type: Research Article
  • Received: March 7, 2015
  • Revised: March 29, 2015
  • Accepted: April 11, 2015
  • DOI: 10.5812/hepatmon.15(5)2015.28473

To Cite: Liu Y, Zou Z, Zhu B, Hu Z, Zeng P, et al. LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes, Hepat Mon. 2015 ; 15(5):e28473. doi: 10.5812/hepatmon.15(5)2015.28473.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Jacobson IM, Davis GL, El-Serag H, Negro F, Trepo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010; 8(11): 924-33[DOI][PubMed]
  • 2. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med. 2014; 7: 387-98[DOI][PubMed]
  • 3. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014; 108: 181-91[DOI][PubMed]
  • 4. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014; 109(5): 628-35[DOI][PubMed]
  • 5. Gunduz F, Mallikarjun C, Balart LA, Dash S. Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection. Exp Mol Pathol. 2014; 96(1): 36-41[DOI][PubMed]
  • 6. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol. 2005; 79(10): 6291-8[DOI][PubMed]
  • 7. Wang C, Pflugheber J, Sumpter RJ, Sodora DL, Hui D, Sen GC, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol. 2003; 77(7): 3898-912[PubMed]
  • 8. Guo JT, Sohn JA, Zhu Q, Seeger C. Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology. 2004; 325(1): 71-81[DOI][PubMed]
  • 9. Pflugheber J, Fredericksen B, Sumpter RJ, Wang C, Ware F, Sodora DL, et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A. 2002; 99(7): 4650-5[DOI][PubMed]
  • 10. Liu YT, Yin HL. Identification of the binding partners for flightless I, A novel protein bridging the leucine-rich repeat and the gelsolin superfamilies. J Biol Chem. 1998; 273(14): 7920-7[PubMed]
  • 11. Choe N, Kwon JS, Kim JR, Eom GH, Kim Y, Nam KI, et al. The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. Atherosclerosis. 2013; 229(2): 348-55[DOI][PubMed]
  • 12. Wilson SA, Brown EC, Kingsman AJ, Kingsman SM. TRIP: a novel double stranded RNA binding protein which interacts with the leucine rich repeat of flightless I. Nucleic Acids Res. 1998; 26(15): 3460-7[PubMed]
  • 13. Nguyen JB, Modis Y. Crystal structure of the dimeric coiled-coil domain of the cytosolic nucleic acid sensor LRRFIP1. J Struct Biol. 2013; 181(1): 82-8[DOI][PubMed]
  • 14. Bagashev A, Fitzgerald MC, Larosa DF, Rose PP, Cherry S, Johnson AC, et al. Leucine-rich repeat (in Flightless I) interacting protein-1 regulates a rapid type I interferon response. J Interferon Cytokine Res. 2010; 30(11): 843-52[DOI][PubMed]
  • 15. Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol. 2010; 11(6): 487-94[DOI][PubMed]
  • 16. Sumpter RJ, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol. 2005; 79(5): 2689-99[DOI][PubMed]
  • 17. Liu Y, Zou Z, Zhu B, Hu Z, Zeng P. CXCL10 decreases GP73 expression in hepatoma cells at the early stage of hepatitis C virus (HCV) infection. Int J Mol Sci. 2013; 14(12): 24230-41[DOI][PubMed]
  • 18. Perales C, Beach NM, Sheldon J, Domingo E. Molecular basis of interferon resistance in hepatitis C virus. Curr Opin Virol. 2014; 8: 38-44[DOI][PubMed]
  • 19. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004; 5(7): 730-7[DOI][PubMed]
  • 20. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A. 2004; 101(49): 17264-9[DOI][PubMed]
  • 21. Suriano AR, Sanford AN, Kim N, Oh M, Kennedy S, Henderson MJ, et al. GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Mol Cell Biol. 2005; 25(20): 9073-81[DOI][PubMed]
  • 22. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003; 4(5): 491-6[DOI][PubMed]
  • 23. Weber F. Interaction of hepatitis C virus with the type I interferon system. World J Gastroenterol. 2007; 13(36): 4818-23[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments